download (1).png
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
March 14, 2024 04:14 ET | Atrogi
SOLNA, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1...
Research Nester Logo.jpg
Chronic Disease Management Market revenue to reach USD 27 Billion by 2035, says Research Nester
March 13, 2024 07:30 ET | Research Nester
New York, March 13, 2024 (GLOBE NEWSWIRE) -- The global chronic disease management market size is projected to grow at a CAGR of over ~13% from 2023 to 2035. The market is expected to garner a...
Fractyl-Logo.png
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024 14:06 ET | Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl-Logo.png
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024 08:38 ET | Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Arecor logo.jpg
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12, 2024 07:30 ET | Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
MannkindLogoStackedPreferd.jpg
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 11, 2024 06:05 ET | MannKind
INHALE-3 STUDY’S INITIAL MEAL CHALLENGE RESULTS COMPARING AFREZZA® HEAD-TO-HEAD WITH MULTIPLE DAILY INJECTIONS (MDI) AND INSULIN PUMPS
logo.png
GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
February 27, 2024 08:30 ET | GlucoTrack, Inc.
Rutherford, NJ & Brooklyn Park, MN, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel...
Simple HealthKit Expanded Kidney Health Test
Simple HealthKit Launches Expanded Kidney Health Evaluation for Patients with Diabetes (KED) Program to Help Payers Improve Patient Health, Boost STAR Ratings & Meet HEDIS Measures
February 26, 2024 09:00 ET | Simple HealthKit
Simple HealthKit has launched a new Kidney Health Evaluation for Patients with Diabetes (KED) program to help healthcare payers improve patient health.
Research Nester Logo.jpg
Auto-Injectors Market revenue to surpass USD 33 Billion by 2036, says Research Nester
February 21, 2024 07:00 ET | Research Nester
New York , Feb. 21, 2024 (GLOBE NEWSWIRE) -- The global auto-injectors market size is predicted to expand at 17% CAGR between 2024 and 2036. The market is projected to garner a revenue of USD 33...
Logo.jpg
LiveCare Inc. (OTCMKTS: LVCE) Announces Stellar Revenue Growth, Strategic Patient Expansion in Telehealth for Diabetes Care, and Aspirations for NASDAQ Listing
February 20, 2024 10:00 ET | LiveCare Inc.
Venice, FL, USA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- LiveCare Inc. (OTCMKTS: LVCE), a leading telehealth company specializing in health coaching and comprehensive services for individuals with...